![{[setting('site_name')]}](https://projxnews.com/uploads/setting/16983847711140531930.webp)
Aarti Pharmalabs has outlined a capital expenditure plan of approximately ₹400 crore for FY2027, broadly in line with its investment outlay for FY2026.
The planned investments will primarily support the ongoing Xanthine expansion project, debottlenecking efforts at the Tarapur Unit-4 facility, and the proposed construction of a new production block at the Atali manufacturing site.
Through these initiatives, the company aims to strengthen its manufacturing capabilities, improve operational efficiency, and support its long-term growth objectives.
News by Rahul Yelligetti.
